This mechanism not only overcomes the negative feedback activation of the PI3K pathway but also provides a new treatment paradigm for PIK3CA-mutated breast cancer by targeting the degradation of oncogenic mutant proteins (Figure 1). Here, PIK3CA is linked to breast cancer.